View in EDS

Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma.

Saved in:

Bibliographic Details
Title:	Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma.
Authors:	van der Horst HJ; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; and., Gelderloos AT; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; and., Chamuleau MED; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; and., Breij ECW; Genmab, Utrecht, The Netherlands., Zweegman S; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; and., Nijhof IS; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; and., Overdijk MB; Genmab, Utrecht, The Netherlands., Mutis T; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; and.
Source:	Blood advances [Blood Adv] 2021 Apr 27; Vol. 5 (8), pp. 2165-2172.
Publication Type:	Journal Article; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	2473-9537
DOI:	10.1182/bloodadvances.2020003731